| Literature DB >> 30200295 |
Charinya Khamphukdee1, Orawan Monthakantirat2, Yaowared Chulikhit3, Suradet Buttachon4,5, Michael Lee6, Artur M S Silva7, Nazim Sekeroglu8, Anake Kijjoa9,10.
Abstract
The previously unreported flavone glycoside, demethyltorosaflavone B (2) and the E-propenoic acid substituted flavone, torosaflavone E (3a), were isolated together with nine previously reported metabolites, including indole-3-carbaldehyde, oleanonic acid, vanillic acid, p-hydroxybenzoic acid, altheranthin (1a), alternanthin B (1b), demethyltorosaflavone D (3b), luteolin 8-C-E-propenoic acid (4) and chrysoeriol 7-O-rhamnoside (5), from the ethanol extract of the aerial part of Althernanthera philoxeroides. The crude ethanol extract was evaluated for its in vitro estrogenic activity in MCF-7 breast cancer cell line. The crude ethanol extract was also investigated in vivo for its antidepressant-like effects on ovariectomized mice using tail suspension and forced swimming tests, while its effect on the locomotor activity was evaluated by a Y-maze test. The effect of the crude extract on the serum corticosterone level, size and volume of uterus of the ovariectomized mice were also investigated. The expression of the mouse cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), brain-derived neurotrophic factor (BDNF) and β-actin mRNAs in hippocampus and frontal cortex was also evaluated, using semiquantitative reverse transcription-polymerase chain reaction. The crude extract and the isolated compounds 1a, 1b, 3a, 3b and 5, were evaluated for their inhibitory effects on monoamine oxidases (MAOs)-A and -B.Entities:
Keywords: Althernanthera philoxeroides; C-E-propenoic substituted flavones; C-glycosylated flavones; MAO inhibitor; antidepressant-like effects; estrogenic activity; ovariectomized mice
Mesh:
Substances:
Year: 2018 PMID: 30200295 PMCID: PMC6225253 DOI: 10.3390/molecules23092202
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Flavonoid constituents of Alternanthera philoxeroides.
Figure 2The effect of a daily administration of 17β-estradiol (E2) and a crude ethanol extract of A. philoxeroides on ovariectomized (OVX)-induced hopeless behaviors in forced swimming tests (FST) (A) and tail suspension test (TST) (B). Immobility time of each animal group was measured as an index of depression. Each data column represents the mean ± SEM (n = 8–10 in each animal group). # p < 0.05 and ## p < 0.01 compared with the vehicle-treated sham group (t-test), ** p < 0.01 compared with the vehicle-treated OVX group (Tukey test) and $$ p < 0.01 compared between different doses.
Figure 3The effect of a daily administration of 17β-estradiol (E2) and ethanol crude extract of A. philoxeroides on a locomotor activity in a Y-maze test. The number of arms entries of each animal group was determined. Each data column represents the mean ± SEM (n= 8–10 in each animal group).
Estrogen level, weight and volume of uterus of OVX mice treated with the ethanol crude extract of A. phliroxeroides (AP) and 17β-estradiol (E2).
| Group | 17β-estradiol (pg/mL) | Uterine Weight (g/kg) | Uterine Volume (cm3/kg) |
|---|---|---|---|
| Sham | 17.91 ± 1.10 ** | 4.105 ± 0.01 ** | 2.500 ± 0.03 ** |
| OVX Vehicle-treated | 8.27 ± 0.32 | 1.675 ± 0.01 | 0.500 ± 0.00 |
| OVX + E2 (1 μg/kg/day) | 24.81 ± 1.11 ** | 3.055 ± 0.04 ** | 2.305 ± 0.02 ** |
| OVX + AP (250 mg/kg/day) | 12.24 ± 0.52 ** | 2.600 ± 0.01 * | 1.143 ± 0.02 ** |
| OVX + AP (500 mg/kg/day) | 13.19 ± 0.01 ** | 3.029 ± 0.01 * | 1.714 ± 0.04 ** |
Data were expressed as mean ± SEM (Serum of estrogen, n = 3–4; Uterine weight and volume, n = 8–12). All post hoc comparisons were vs. vehicle-treated OVX group by one-way ANOVA. ** p < 0.001 and * p < 0.05.
Figure 4The effect of the ethanol crude extract of A. philoxeroides on the corticosterone level. Each column represents the mean ± SEM (n = 3–5). ## p < 0.001 vs. sham-operated group, ** p < 0.001 vs. OVX group and $$ p < 0.001 vs. A. philoxeroides-treated group (post hoc Tukey test).
Figure 5Effect of the A. philoxeroides extract on the expression levels of cyclic AMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) mRNAs in the hippocampus (A) and frontal cortex (B) of sham and OVX mice. The expression of BDNF and CREB mRNAs were semi-quantitatively analyzed as described in the text. Each data column represents the mean ± SEM (n = 4–6 in each animal group). # p < 0.05, ## p < 0.01, compared with the vehicle-treated sham group (t-test), * p < 0.05, ** p < 0.01, compared with vehicle-treated OVX group (Tukey test) and $ p < 0.05 and $$ p < 0.01 compared between different doses.
Inhibitory effect of the ethanol crude extract of A. philoxeroides and 1a, 1b, 3a, 3b and 5 on monoamine oxidase (MAO)-A and MAO-B.
| IC50 (μM) | Si | |||||
|---|---|---|---|---|---|---|
| Extract/compound | MAO-A | MAO-B | MAO-A | MAO-B | MAO-A | MAO-B |
| Extract of | 252.9 ± 0.02 | 90.69 ± 0.02 | 66.640 | 39.0640 | 1.7050 | 0.5860 |
|
| 0.00046 ± 0.04 | 0.00060 ± 0.12 | 0.00012 | 0.00026 | 0.4681 | 2.1364 |
|
| 0.00206 ± 0.04 | 0.00022 ± 0.12 | 0.00054 | 0.00010 | 5.6681 | 0.1764 |
|
| 18.37 ± 1.47 | 0.6748 ± 0.46 | 4.8405 | 0.2900 | 16.6534 | 0.0601 |
|
| 0.0541 ± 0.01 | 0.1293 ± 0.42 | 0.1328 | 0.0557 | 2.3850 | 0.4193 |
|
| 3.051 ± 0.35 | 0.5441 ± 0.33 | 0.8039 | 0.2344 | 3.4303 | 0.2915 |
| Clorgyline * | 0.0016 ± 0.05 | 0.4130 ± 0.08 | 0.0004 | 0.1779 | 0.0024 | 421.950 |
| Deprenyl ** | 6.579 ± 0.05 | 2.024 ± 0.04 | 1.7336 | 0.8718 | 1.9885 | 0.5029 |
All data are expressed as mean ± SD. * Clorgyline is a reference for selective of MAO-A inhibitor, ** Deprenyl is a reference for selective of MAO-B inhibitor. Ki is the corresponding enzyme-inhibitor dissociation constant and Si is the selectivity index between MAO-A and MAO-B.
1H- and 13C-NMR (DMSO-d6, 500.13 and 125.4 MHz) and HMBC assignment for 2.
| Position | δC, Type | δH, ( | COSY | HMBC |
|---|---|---|---|---|
| 2 | 164.1, C | - | ||
| 3 | 102.8, CH | 6.70, s | C-2, 4, 4a, 1′ | |
| 4 | 181.9, CO | - | ||
| 4a | 103.0, C * | - | ||
| 5 | 157.5, C | - | ||
| 6 | 110.1, C | - | ||
| 7 | 162.0, C | - | ||
| 8 | 94.6, CH | 6.52, s | C-4a, 6, 7, 8a | |
| 8a | 156.1, C | - | ||
| 1′ | 121.5, C * | - | ||
| 2′ | 113.4, CH | 7.41, d (2.2) | H-6′ | C-2, 3′, 4′ |
| 3′ | 145.8, C | - | ||
| 4′ | 150.0, C | - | ||
| 5′ | 116.0, CH | 6.89, d (8.4) | H-6′ | C-1′, 3′, 4′ |
| 6′ | 119.1, CH | 7.43, dd (8.4, 2.2) | H-2′, 5′ | C-2, 2′, 4′ |
| 1″ | 70.1, CH | 4.99, dd (11.9, 2.9 | H-2″ | |
| 2″ | 32.4, CH2 | 2.05, q (11.7) | H-1″ | |
| 1.60, m | H-1″ | |||
| 3″ | 68.5, CH | 3.71, m | H-4″ | |
| 4″ | 69.6, CH | 3.45 ** | H-3″ | |
| 5″ | 74.4, CH | 3.65, q (6.4) | H-6″ | |
| 6″ | 1.18, CH3 | 1.18, d (6.4) | H-5″ | C-4″, 5″ |
| OH-5 | - | 13.53, s |
* observed in HMBC spectrum, ** under the water peak.
1H- and 13C-NMR (DMSO-d6, 500.13 and 125.4 MHz) and HMBC assignment for 3a.
| Position | δC, Type | δH, ( | COSY | HMBC | NOESY |
|---|---|---|---|---|---|
| 2 | 163.7, C | - | - | ||
| 3 | 103.1, CH | 6.96, s | C-4, 4a | ||
| 4 | 181.4, CO | - | |||
| 4a | 1028, C | - | |||
| 5 | 161.8, C | - | |||
| 6 | 106.0, C | - | |||
| 7 | 163.6, C | - | |||
| 8 | 94.0, CH | 6.55, s | C-4a, 6, 8a | ||
| 8a | 157.4, C | - | |||
| 1′ | 121.3, C | - | |||
| 2′ | 110.2, CH | 7.57, brs | C-4′, 6′ | OMe | |
| 3′ | 148.1, C | - | |||
| 4′ | 150.9, C | - | |||
| 5′ | 115.8, CH | 6.95, d (8.2) | C-1′, 2′, 3′, 4′ | ||
| 6′ | 120.5, CH | 7.58, dd (8.2, 2.1) | C-2, 2′, 4′ | ||
| 1″ | 134.0, CH | 7.91, d (16.2) | 2″, 3″, 5, 7 | ||
| 2″ | 119.6, CH | 6.86, d (16.2) | 3″, 6 | ||
| 3″ | 168.8, CO | - | |||
| OMe-3′ | 56.0, CH3 | 3.89, s | C-3′ | H-2′ | |
| OH-5 | - | 14.45, s | C-4a, 5, 6 | ||
| OH-3″ | - | 10.06, br |